Figure 3From: VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Survival analysis under FLO/FLP treatment in regards of CXCR4 expression in an observation period of 5Â years. A. CXCR4 negative. B. CXCR4 positive.Back to article page